Abstract
The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive impairment (MCI), (2) delirium-onset, and (3) psychiatric-onset presentations. The purpose of our review is to determine whether there is sufficient information yet available to justify development of diagnostic criteria for each of these. Our goal is to achieve evidence-based recommendations for the recognition of DLB at a predementia, symptomatic stage. We propose operationalized diagnostic criteria for probable and possible mild cognitive impairment with Lewy bodies, which are intended for use in research settings pending validation for use in clinical practice. They are compatible with current criteria for other prodromal neurodegenerative disorders including Alzheimer and Parkinson disease. Although there is still insufficient evidence to propose formal criteria for delirium-onset and psychiatric-onset presentations of DLB, we feel that it is important to characterize them, raising the index of diagnostic suspicion and prioritizing them for further investigation.
Original language | English (US) |
---|---|
Pages (from-to) | 743-755 |
Number of pages | 13 |
Journal | Neurology |
Volume | 94 |
Issue number | 17 |
DOIs | |
State | Published - Apr 28 2020 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'Research criteria for the diagnosis of prodromal dementia with Lewy bodies'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Research criteria for the diagnosis of prodromal dementia with Lewy bodies. / McKeith, Ian G.; Ferman, Tanis J.; Thomas, Alan J.; Blanc, Frédéric; Boeve, Bradley F.; Fujishiro, Hiroshige; Kantarci, Kejal; Muscio, Cristina; O'Brien, John T.; Postuma, Ronald B.; Aarsland, Dag; Ballard, Clive; Bonanni, Laura; Donaghy, Paul; Emre, Murat; Galvin, James E.; Galasko, Douglas; Goldman, Jennifer G.; Gomperts, Stephen N.; Honig, Lawrence S.; Ikeda, Manabu; Leverenz, James B.; Lewis, Simon J.G.; Marder, Karen S.; Masellis, Mario; Salmon, David P.; Taylor, John Paul; Tsuang, Debby W.; Walker, Zuzana; Tiraboschi, Pietro.
In: Neurology, Vol. 94, No. 17, 28.04.2020, p. 743-755.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Research criteria for the diagnosis of prodromal dementia with Lewy bodies
AU - McKeith, Ian G.
AU - Ferman, Tanis J.
AU - Thomas, Alan J.
AU - Blanc, Frédéric
AU - Boeve, Bradley F.
AU - Fujishiro, Hiroshige
AU - Kantarci, Kejal
AU - Muscio, Cristina
AU - O'Brien, John T.
AU - Postuma, Ronald B.
AU - Aarsland, Dag
AU - Ballard, Clive
AU - Bonanni, Laura
AU - Donaghy, Paul
AU - Emre, Murat
AU - Galvin, James E.
AU - Galasko, Douglas
AU - Goldman, Jennifer G.
AU - Gomperts, Stephen N.
AU - Honig, Lawrence S.
AU - Ikeda, Manabu
AU - Leverenz, James B.
AU - Lewis, Simon J.G.
AU - Marder, Karen S.
AU - Masellis, Mario
AU - Salmon, David P.
AU - Taylor, John Paul
AU - Tsuang, Debby W.
AU - Walker, Zuzana
AU - Tiraboschi, Pietro
N1 - Funding Information: The Article Processing Charge was funded by the NIHR Newcastle Biomedical Research Centre. Funding Information: I. McKeith receives support from the NIHR Biomedical Research Centre awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University and has consulted for GE Healthcare, Sanofi, Eisai, Sumitomo Dai-nippon Pharma, and Axovant. T. Ferman receives support from NIH P50-AG16574, P30-AG062677, U01-NS100620, and the Mangurian Foundation for Lewy body disease research. A. Thomas receives support from the NIHR Biomedical Research Centre awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University and has received grants from GE Healthcare. F. Blanc has served as national clinical trial coordinator for Eisai and Axovant. B. Boeve receives support from NIH P50-AG16574, P30-AG062677, U01-NS100620, and the Mangurian Foundation for Lewy body disease research; has consulted for the ScientificAdvisory Board—Tau Consortium; and received grants from Biogen, the NIH, the Mangurian Foundation, Alector, the Little Family Foundation, and the Turner Family. H. Fujishiro has received support from Fujifilm RI Pharma Co Ltd. K. Kantarci receives support from NIH P50-AG16574, P30-AG062677, U01-NS100620, and the Mangurian Foundation for Lewy body disease research and has received grants from Avid Radiopharmaceuticals and acted on a Data Safety Monitoring Board for Takeda Global Research. C. Muscio acknowledges the support of the Italian Ministry of Health GRANT NET-2011-02346784. J. O’Brien is supported by the NIHR Cambridge Biomedical Research Centre Dementia and Neuro-degeneration and Mental Health Themes and the Cambridge Centre for Parkinson’s Plus Disorders; has consulted for TauRx, Axon, GE Healthcare, Eisai, and Avid/Lilly; and received grants from Avid/Lilly and Alliance Medical. R. Postuma has received grants from and consulted for Fonds de la Recherche en Sante; received grants from the Canadian Institutes of Health Research, the Parkinson Society of Canada, the Weston-Garfield Foundation, The Michael J. Fox Foundation, and the Webster Foundation; and consulted for Takeda, Roche/Prothena, Teva Neurosciences, Novartis Canada, Biogen Boehringer Ingelheim, Theranexus, GE Healthcare, Jazz Pharmaceuticals, AbbVie, Jannsen, Otsuko, Phytopharmics, Inception Sciences, and Parkinson Canada. D. Aarsland is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation and the Royal Society for their support. He has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals, and GE Health and served as paid consultant for H. Lundbeck, Eisai, Heptares, Sanofi, and Mentis Cura. C. Ballard reports unrelated current grant funding from MRC, Wellcome Trust, European Union, Gillings Foundation, NIHR, Alzheimer’s Society, Alzheimer’s Research UK, Parkinson’s Society, and Lewy Body Society during the conduct of the study and personal fees from Acadia pharmaceutical company, Lundbeck, Roche, Otsuka, Eli Lilly, and AARP outside the submitted work. L. Bonanni is a member of the steering committee of the E-DLB consortium and program chair of the LBD-PIA (ISTAART), and is funded for research on DLB by the Italian Ministry of Health. P. Donaghy receives support from the NIHR Biomedical Research Centre awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. M. Emre served on the scientific advisory board for AC Immune. J. Galvin receives support from NIH grants (R01 AG040211, R01 NS101482, R01 AG057681, and U01 NS100610) and the Lewy Body Dementia Association Research Center of Excellence; reports research support from the NIH, the Lewy Body Dementia Association, The Harry T. Mangurian Foundation, and Albert Charitable Trust; directs clinical trials for Biogen and Novartis; receives licensing fees from Biogen, Roche, Eli Lilly, Quintiles, Roobrik, Continuum Clinical, and Langland; and receives consulting fees from Biogen, Eisai, Bracket, and Medavante. D. Galasko receives support from NIA grant AGO5131 and the Michael J Fox Foundation and has acted as consultant for vTv Pharmaceuticals Inc, Esai, Inc., and for Fujirebio Inc; been a member of a DSMB for Probiodrug, and paid editor for Alzheimer’s Research & Therapy. J. Goldman receives grant/support from The Michael J. Fox Foundation and Parkinson’s Foundation and has received consulting fees/honoraria from Acadia, Aptinyx, Sunovion, and Worldwide Med. S Gomperts receives support from NIH grants R01 AG054551, P30AG062421, R01 AG062208, P50 AG005134, R21 NS109833, DOD CDMRP/W81XW1810516, the Farmer Family Parkinson’s Initiative, and the Lewy Body Dementia Association and has served on advisory boards for Acadia Pharmaceuticals and Sanofi. L. Honig acknowledges research grant support from NYS CEAD grant C031425, LBDA RCOE, and NIH grants U01NS100600, P50AG008702, R21AG058020, R21MH111596, U01AG051412, U01AG045390, U01AG016976, U01AG023749, U19063893, and U19AG024904. He receives research funding support from AbbVie, Alector, Biogen, Eisai, Genentech, Roche, and Washington University and has received income for consulting for Cortexyme and Eisai. M. Ikeda reports departmental grants and honoraria fees from Sumitomo Dainippon Pharma, Eisai, and Niho Medicine-Physics. J. Leverenz acknowledges support from the National Institutes of Health: P30 AG053762, UO1 NS100610, and R13 NS111954, and Jane and Lee Seidman and Douglas Herthel DVM Memorial Funds and reports consulting fees from Aptinyx, Acadia, Biogen, Eisai, GE Healthcare, Genzyme/Sanofi, and Takeda Pharmaceuticals and grant support from Alzheimer’s Drug Discovery Foundation, Department of Defense, GE Healthcare, Genzyme/Sanofi, The Michael J. Fox Foundation, and the NIH (NIA and NINDS). S. Lewis is supported by NHMRC-ARC Dementia Fellows. K. Marder is funded by the NIH: R01NS100600, NS107168, UL1TR001873, and NS073671, with research support from the LBDA, Parkinson Foundation, Michael J. Fox, HDSA, and CHDI, and has acted as site investigator for Vaccinex and Genentech, member of Springer editorial board, and scientific advisory board, Voyager Therapeutics. M. Masellis was supported by a Canadian Institutes of Health Research grant (MOP13129) and an Early Researcher Award from the Ministry of Research, Innovation, and Science (MRIS; ON) and reports personal fees for ad hoc consultancy from Arkuda Therapeutics, Ionis Pharmaceuticals, and Alector Pharmaceuticals, royalties from Henry Stewart Talks Ltd., and grants to the institution from Roche, Novartis, Washington University, and Axovant Sciences. D. Salmon acknowledges support from NIH P30AG062429 and is a paid consultant for Takeda, Inc., Apti-nyx, Inc., and Biogen, Inc. J-P. Taylor receives support from the NIHR Biomedical Research Centre awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University and reports grants from the UK National Institute of Health Research (NIHR), travel award from Axovant, research support costs from Sonsei-Heptares, and personal fees from GE Healthcare. D. Tsuang acknowledges support from NIH R21AG064271, R03 NS103950, and U01 NS100610. Z. Walker has been supported by ESRC NIHR (co-app), ARUK (co-app), EU IMI 2 (co-app), and Dunhill Medical Trust. She has received consultancy fees, travel expenses, and research support from GE Healthcare and research support from Life Molecular Imaging. P. Tiraboschi acknowledges the support of the Italian Ministry of Health GRANT NET-2011-02346784. Go to Neurology.org/N for full disclosures. Publisher Copyright: © American Academy of Neurology. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/28
Y1 - 2020/4/28
N2 - The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive impairment (MCI), (2) delirium-onset, and (3) psychiatric-onset presentations. The purpose of our review is to determine whether there is sufficient information yet available to justify development of diagnostic criteria for each of these. Our goal is to achieve evidence-based recommendations for the recognition of DLB at a predementia, symptomatic stage. We propose operationalized diagnostic criteria for probable and possible mild cognitive impairment with Lewy bodies, which are intended for use in research settings pending validation for use in clinical practice. They are compatible with current criteria for other prodromal neurodegenerative disorders including Alzheimer and Parkinson disease. Although there is still insufficient evidence to propose formal criteria for delirium-onset and psychiatric-onset presentations of DLB, we feel that it is important to characterize them, raising the index of diagnostic suspicion and prioritizing them for further investigation.
AB - The prodromal phase of dementia with Lewy bodies (DLB) includes (1) mild cognitive impairment (MCI), (2) delirium-onset, and (3) psychiatric-onset presentations. The purpose of our review is to determine whether there is sufficient information yet available to justify development of diagnostic criteria for each of these. Our goal is to achieve evidence-based recommendations for the recognition of DLB at a predementia, symptomatic stage. We propose operationalized diagnostic criteria for probable and possible mild cognitive impairment with Lewy bodies, which are intended for use in research settings pending validation for use in clinical practice. They are compatible with current criteria for other prodromal neurodegenerative disorders including Alzheimer and Parkinson disease. Although there is still insufficient evidence to propose formal criteria for delirium-onset and psychiatric-onset presentations of DLB, we feel that it is important to characterize them, raising the index of diagnostic suspicion and prioritizing them for further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85084763016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084763016&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000009323
DO - 10.1212/WNL.0000000000009323
M3 - Review article
C2 - 32241955
AN - SCOPUS:85084763016
VL - 94
SP - 743
EP - 755
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 17
ER -